Plasminogen activator inhibitor-1: A common denominator in obesity, diabetes and cardiovascular disease

Bart De Taeye, L. Harris Smith, Douglas E. Vaughan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

147 Scopus citations

Abstract

A classical perspective of cardiovascular risk does not adequately account for all of the cardiovascular events associated with obesity and diabetes. The combination of hypertriglyceridemia, glucose intolerance and inflammation is linked with increased production of the primary inhibitor of endogenous thrombolysis, plasminogen activator inhibitor-1 (PAI-1). Recent data suggest that PAI-1 contributes directly to the complications of obesity, including type 2 diabetes, coronary arterial thrombi, and may even influence the accumulation of visceral fat. Therefore, direct inhibition of PAI-1 might not only provide a new therapeutic strategy for reducing cardiovascular risk, but may also have beneficial effects on obesity and insulin resistance.

Original languageEnglish (US)
Pages (from-to)149-154
Number of pages6
JournalCurrent Opinion in Pharmacology
Volume5
Issue number2 SPEC. ISS.
DOIs
StatePublished - Apr 2005

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Plasminogen activator inhibitor-1: A common denominator in obesity, diabetes and cardiovascular disease'. Together they form a unique fingerprint.

Cite this